---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060408"
form_type: "8-K"
ticker: null
cik: "0001445283"
company_name: "KINETA, INC./DE"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:52:04.394611+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kineta Q1 2024 net loss $10.2M; cash $1.8M; going concern doubt; exploring strategic alternatives

## Summary
- Cash of $1.8M as of March 31, 2024, down from $5.8M at year-end 2023; received $500K from existing investor in April 2024.
- Net loss of $10.2M ($0.89 per share) vs. $6.5M ($0.77 per share) in Q1 2023; no revenue in Q1 2024.
- Substantial doubt about ability to continue as a going concern; actively exploring strategic alternatives to maximize stockholder value.
- Phase 1/2 VISTA-101 trial for KVA12123 shows partial response in combination cohort and durable stable disease; enrollment of new patients suspended.
- Company reduced workforce and suspended new patient enrollment after some investors failed to fund April 2024 private placement obligation; litigation pursued against larger non-funding investors.

## SEC filing metadata
- accession: 0000950170-24-060408
- form_type: 8-K
- cik: 0001445283
- company_name: KINETA, INC./DE
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445283/000095017024060408/0000950170-24-060408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445283/000095017024060408/ka-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060408
- JSON: https://secwatch.observer/filing/0000950170-24-060408.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060408.txt

## Key facts
- Earnings Releases
  KINETA, INC./DE reported the three months ended March 31, 2024 results: revenue zero, net income $10.2 million, EPS $0.89.
  - Period: the three months ended March 31, 2024
  - Revenue: zero
  - Net income: $10.2 million
  - EPS: $0.89
  - Result: reported results
  source text: Net loss was $10.2 million, or $0.89 per basic and diluted share, for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445283/000095017024060408/0000950170-24-060408-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.